Furthermore, compared to IP-administered saline and free anti-PD-L1 mAb controls, anti-PD-L1-NP induced superior tumor regressions, and immunohistochemistry (IHC) on treated tumors revealed an increase in tumor-infiltrating CD8+ and CD4+ T cells only in the anti-PD-L1-NP group. The gene discussed is CD4; the disease is neoplasm.